• If you are wondering whether West Pharmaceutical Services is starting to offer better value or still looks expensive at around US$231.12 a share, you are not alone.
• The stock is currently down 2.3% over the last week, 16.4% over the past month, and 32.0% over the past year, which may signal that expectations and perceived risk around the company have shifted.
• Recent coverage has focused on how the share price has pulled back over multiple time frames, including the year to date return of 16.4% and the 3 year and 5 year returns of 14.6% and 19.7% respectively. This puts longer term performance in context and has prompted more investors to reassess whether the current price fairly reflects the company's prospects or has moved out of line with fundamentals.
• On Simply Wall St's valuation checks, West Pharmaceutical Services scores 2 out of 6, and you can see the breakdown in the valuation score. Next, we will look at what different valuation methods say about the stock, and then finish with a simpler way to judge value that ties everything together.

West Pharmaceutical Services scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: West Pharmaceutical Services Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth today by projecting its future cash flows and then discounting those back to a present value.

For West Pharmaceutical Services, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $336.7 million. Analysts provide explicit forecasts up to 2026, where Free Cash Flow is projected at $453 million. Beyond that, Simply Wall St extrapolates further, with ten year projections that extend out to 2035 in the same currency, $.

When all of those projected cash flows are discounted back and combined, the model arrives at an estimated intrinsic value of about $162.13 per share. Compared to the recent share price of roughly $231.12, the DCF output suggests the stock is around 42.5% more expensive than this intrinsic value estimate. This points to an overvalued reading based purely on these cash flow assumptions.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests West Pharmaceutical Services may be overvalued by 42.5%. Discover 875 undervalued stocks or create your own screener to find better value opportunities.

Approach 2: West Pharmaceutical Services Price vs Earnings

For a profitable business like West Pharmaceutical Services, the P/E ratio is a useful shortcut because it links what you pay per share directly to the earnings the company is already generating.

What counts as a “normal” P/E depends a lot on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk usually means investors look for a lower multiple.

West Pharmaceutical Services is currently trading on a P/E of about 33.8x. That sits below the Life Sciences industry average P/E of roughly 37.3x, but above the peer group average of around 31.6x. Simply Wall St also calculates a proprietary “Fair Ratio” of 24.6x, which is the P/E level they would expect given factors such as the company’s earnings growth profile, profit margins, industry, market cap and specific risks.

This Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific characteristics rather than assuming one size fits all. When compared with this Fair Ratio of 24.6x, the current P/E of 33.8x suggests the shares are trading above the level implied by those fundamentals.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1426 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your West Pharmaceutical Services Narrative

Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, which let you put a clear story behind the numbers, including your view of fair value and your estimates for future revenue, earnings and margins.

A Narrative links what you believe about a company’s business to a financial forecast, and then to a fair value that you can compare directly with the current share price.

On Simply Wall St, Narratives sit inside the Community page and are designed to be easy to use. This means you can quickly see how your view of West Pharmaceutical Services translates into numbers without building a full model yourself.

Each Narrative helps you assess whether the stock looks appealing by setting a Fair Value and placing it side by side with the live market Price. It automatically refreshes when new information such as earnings releases or major news is added to the platform.

For example, one West Pharmaceutical Services Narrative might set a relatively low fair value with cautious revenue and margin assumptions. Another might set a higher fair value based on stronger revenue expectations and steady profitability. This gives you a clear view of how different perspectives compare.

Do you think there's more to the story for West Pharmaceutical Services? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.